Physiomics reports fall in operating loss, rise in turnover

UK biology company Physiomics said operating loss dropped 6.3 per cent in the last half of 2012 as the group signed on new clients and progressed in research and development of products.

UK biology company Physiomics said operating loss dropped 6.3 per cent in the last half of 2012 as the group signed on new clients and progressed in research and development of products.

Operating loss came to £307,685, compared to £328,674 for the same period a year ago, as turnover increased 52.9% to £52,000.

The firm said it signed on a "top five" global pharmaceutical client during the period and was in discussions with others about licencing technology and entering into long-term contracts.

A £4.0m Standby Equity Distribution Agreement was signed with Yorkville, strengthening the position of the company for future growth and acquisition.

Physiomics advanced in developing two new technologies - DrugCARD database and Cardiac toxicity prediction service - which will be launched this year.

First stage of development of the group's Virtual Tumour Clinical, a computer model which analyses tumour cells, is underway as the company works closely with drug discovery and development groups.

"Significant progress has been made during the half year," the group said.

"The customer base has been increased, relationships with existing customers are progressing, new products are soon to come on line and the company's flagship Virtual Tumour Clinical project has begun in earnest, with large pharma already showing an interest in assisting its development.

"While progress on the sales front has been slower than the directors hoped, they believe that the company is establishing the level of credibility required to convert more prospects and is well positioned to deliver more stable sales in the near-term. Successful launch of Virtual Tumour Clinical has the potential to achieve a step-change in growth of revenues."

Shares rose 8.33% to 0.13 at 09:44 Thursday.

RD

Recommended

Broker safety – your questions answered
Investment strategy

Broker safety – your questions answered

Cris Sholto Heaton answers more of your questions about the safety of stockbroker accounts
25 Mar 2020
How demographics affects stock valuations
Investment strategy

How demographics affects stock valuations

New research suggests that stock and bond valuations are driven by the age of the population – at least in the US.
24 Feb 2020
Do you own shares in Sirius Minerals? Here’s what you need to do now
Stocks and shares

Do you own shares in Sirius Minerals? Here’s what you need to do now

Mining giant Anglo American has proposed a cash takeover of Yorkshire-based minnow Sirius Minerals. Unhappy shareholders must decide whether to accept…
20 Feb 2020
Why investors should be “cautiously bullish” for 2020
Stockmarkets

Why investors should be “cautiously bullish” for 2020

Analysts have been out in force making rosy predictions for stockmarkets in 2020, but while there is certainly a case for optimism, investors should r…
17 Jan 2020

Most Popular

The rising dollar is proving bad news for most other assets – will it last?
Investment strategy

The rising dollar is proving bad news for most other assets – will it last?

Precious metals, stocks and pretty much every other asset has taken a tumble as the US dollar strengthens. Dominic Frisby looks at how long this trend…
23 Sep 2020
Oil producers are back at their Covid-19 lows – is it time to buy?
Oil

Oil producers are back at their Covid-19 lows – is it time to buy?

With demand for oil hammered by Covid-19 and talk of “peak oil demand”, there are lots of good reasons to be bearish on oil producers. So, asks John S…
22 Sep 2020
Why you should stuff your end-of-pandemic portfolio with Chinese stocks
China stockmarkets

Why you should stuff your end-of-pandemic portfolio with Chinese stocks

For an end-of-pandemic portfolio, you need assets that can cope with today’s volatility. And that, says Merryn Somerset Webb, means Chinese stocks.
14 Sep 2020